Q3 EPS Estimate for Cooper Companies Increased by Analyst

The Cooper Companies, Inc. (NASDAQ:COO - Free Report) - Equities researchers at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for shares of Cooper Companies in a research report issued on Tuesday, December 24th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical device company will earn $1.05 per share for the quarter, up from their prior forecast of $1.04. The consensus estimate for Cooper Companies' current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies' FY2025 earnings at $3.98 EPS, Q1 2026 earnings at $1.02 EPS, Q2 2026 earnings at $1.06 EPS, Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.42 EPS and FY2027 earnings at $4.86 EPS.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period in the prior year, the firm posted $0.87 earnings per share. The company's quarterly revenue was up 9.8% on a year-over-year basis.

Other analysts have also issued research reports about the company. Needham & Company LLC reiterated a "hold" rating on shares of Cooper Companies in a report on Friday, December 6th. Wells Fargo & Company increased their price target on Cooper Companies from $115.00 to $118.00 and gave the company an "overweight" rating in a research note on Friday, December 6th. Robert W. Baird boosted their price target on Cooper Companies from $118.00 to $125.00 and gave the stock an "outperform" rating in a research note on Thursday, August 29th. Piper Sandler lifted their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, August 29th. Finally, StockNews.com lowered shares of Cooper Companies from a "buy" rating to a "hold" rating in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $117.00.

Cooper Companies Stock Down 0.3 %

NASDAQ:COO traded down $0.27 during midday trading on Friday, reaching $92.34. 671,750 shares of the stock traded hands, compared to its average volume of 1,173,000. The stock has a market capitalization of $18.43 billion, a PE ratio of 47.35, a price-to-earnings-growth ratio of 2.52 and a beta of 0.97. Cooper Companies has a 12-month low of $84.76 and a 12-month high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The business has a 50-day moving average of $100.66 and a two-hundred day moving average of $98.82.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp grew its holdings in Cooper Companies by 1.2% in the third quarter. State Street Corp now owns 8,590,689 shares of the medical device company's stock valued at $947,897,000 after purchasing an additional 104,521 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its position in Cooper Companies by 3.0% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company's stock worth $682,738,000 after acquiring an additional 231,155 shares during the period. JPMorgan Chase & Co. lifted its holdings in Cooper Companies by 13.2% during the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company's stock valued at $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Cooper Companies by 1.0% in the third quarter. Geode Capital Management LLC now owns 4,796,556 shares of the medical device company's stock valued at $527,476,000 after purchasing an additional 48,559 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Cooper Companies by 23.0% during the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company's stock worth $435,856,000 after purchasing an additional 737,726 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.